Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis
Galactomannan (GM) is a polysaccharide present in the cell wall of Aspergillus spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmacokinetics and pharmacodynamics 2017-04, Vol.44 (2), p.143-151 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | 2 |
| container_start_page | 143 |
| container_title | Journal of pharmacokinetics and pharmacodynamics |
| container_volume | 44 |
| creator | Kovanda, Laura L. Desai, Amit V. Hope, William W. |
| description | Galactomannan (GM) is a polysaccharide present in the cell wall of
Aspergillus
spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its implementation in the clinic as a diagnostic tool, GM has been used in experimental models to measure therapeutic response. Several clinical studies describe the prognostic value of GM. Herein, we review the evidence supporting the utilization of GM antigen as a biomarker to measure response to systemic antifungal therapy. |
| doi_str_mv | 10.1007/s10928-017-9509-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1891872194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4321356049</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-4b4a8272360ef3941aaa62d2ea2a78076c8c8ac43347734e0b6974b5382103e73</originalsourceid><addsrcrecordid>eNqNkc9qFTEUhwdRbK0-gBsJuHEzmn-TZNxJqbZQ0EUL7sK5uWduU2aSMclc6SP41ma4VaQgdBFOCN_5Djm_pnnN6HtGqf6QGe25aSnTbd_RvmVPmmPWadEaLeXT9a50W8_3o-ZFzreUMtVx-rw54oYZxoQ6bn59S3EXYi7ekT2MC5I4kB2M4EqcIAQIH4lbUsJQCO79FoNDMsREphh8icmHHUmY5xgykhIJhOKHJVQDKTeYYL4jPpAZiq-GTH76clMf9pD9HgnkGdPOj2PMPr9sng0wZnx1X0-a689nV6fn7eXXLxenny5bJ2lXWrmRYLjmQlEcRC8ZACi-5QgctKFaOeMMOCmE1FpIpBvVa7nphOGMCtTipHl38M4p_lgwFzv57HAcIWBcsmWmZ0Zz1stHoEqpdfOmom8foLdxSaF-pFKGG9NJvs5mB8qlmHPCwc7JT5DuLKN2jdQeIrU1UruKLas9b-7Ny2bC7d-OPxlWgB-APK9xYPpn9H-tvwGHl63I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1882885427</pqid></control><display><type>article</type><title>Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kovanda, Laura L. ; Desai, Amit V. ; Hope, William W.</creator><creatorcontrib>Kovanda, Laura L. ; Desai, Amit V. ; Hope, William W.</creatorcontrib><description>Galactomannan (GM) is a polysaccharide present in the cell wall of
Aspergillus
spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its implementation in the clinic as a diagnostic tool, GM has been used in experimental models to measure therapeutic response. Several clinical studies describe the prognostic value of GM. Herein, we review the evidence supporting the utilization of GM antigen as a biomarker to measure response to systemic antifungal therapy.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1007/s10928-017-9509-1</identifier><identifier>PMID: 28181136</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antifungal Agents - pharmacology ; Aspergillosis - drug therapy ; Aspergillus ; Aspergillus - drug effects ; Aspergillus - metabolism ; Biochemistry ; Biomarkers - metabolism ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Humans ; Mannans - metabolism ; Pharmacology/Toxicology ; Pharmacy ; Prognosis ; Review Paper ; Veterinary Medicine/Veterinary Science</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.143-151</ispartof><rights>Springer Science+Business Media New York 2017</rights><rights>Journal of Pharmacokinetics and Pharmacodynamics is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-4b4a8272360ef3941aaa62d2ea2a78076c8c8ac43347734e0b6974b5382103e73</citedby><cites>FETCH-LOGICAL-c405t-4b4a8272360ef3941aaa62d2ea2a78076c8c8ac43347734e0b6974b5382103e73</cites><orcidid>0000-0002-4493-4652</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10928-017-9509-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10928-017-9509-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>313,314,780,784,792,27922,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28181136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kovanda, Laura L.</creatorcontrib><creatorcontrib>Desai, Amit V.</creatorcontrib><creatorcontrib>Hope, William W.</creatorcontrib><title>Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>Galactomannan (GM) is a polysaccharide present in the cell wall of
Aspergillus
spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its implementation in the clinic as a diagnostic tool, GM has been used in experimental models to measure therapeutic response. Several clinical studies describe the prognostic value of GM. Herein, we review the evidence supporting the utilization of GM antigen as a biomarker to measure response to systemic antifungal therapy.</description><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillus</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus - metabolism</subject><subject>Biochemistry</subject><subject>Biomarkers - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Humans</subject><subject>Mannans - metabolism</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Prognosis</subject><subject>Review Paper</subject><subject>Veterinary Medicine/Veterinary Science</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkc9qFTEUhwdRbK0-gBsJuHEzmn-TZNxJqbZQ0EUL7sK5uWduU2aSMclc6SP41ma4VaQgdBFOCN_5Djm_pnnN6HtGqf6QGe25aSnTbd_RvmVPmmPWadEaLeXT9a50W8_3o-ZFzreUMtVx-rw54oYZxoQ6bn59S3EXYi7ekT2MC5I4kB2M4EqcIAQIH4lbUsJQCO79FoNDMsREphh8icmHHUmY5xgykhIJhOKHJVQDKTeYYL4jPpAZiq-GTH76clMf9pD9HgnkGdPOj2PMPr9sng0wZnx1X0-a689nV6fn7eXXLxenny5bJ2lXWrmRYLjmQlEcRC8ZACi-5QgctKFaOeMMOCmE1FpIpBvVa7nphOGMCtTipHl38M4p_lgwFzv57HAcIWBcsmWmZ0Zz1stHoEqpdfOmom8foLdxSaF-pFKGG9NJvs5mB8qlmHPCwc7JT5DuLKN2jdQeIrU1UruKLas9b-7Ny2bC7d-OPxlWgB-APK9xYPpn9H-tvwGHl63I</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Kovanda, Laura L.</creator><creator>Desai, Amit V.</creator><creator>Hope, William W.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-4493-4652</orcidid></search><sort><creationdate>20170401</creationdate><title>Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis</title><author>Kovanda, Laura L. ; Desai, Amit V. ; Hope, William W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-4b4a8272360ef3941aaa62d2ea2a78076c8c8ac43347734e0b6974b5382103e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillus</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus - metabolism</topic><topic>Biochemistry</topic><topic>Biomarkers - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Humans</topic><topic>Mannans - metabolism</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Prognosis</topic><topic>Review Paper</topic><topic>Veterinary Medicine/Veterinary Science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kovanda, Laura L.</creatorcontrib><creatorcontrib>Desai, Amit V.</creatorcontrib><creatorcontrib>Hope, William W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kovanda, Laura L.</au><au>Desai, Amit V.</au><au>Hope, William W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><stitle>J Pharmacokinet Pharmacodyn</stitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>44</volume><issue>2</issue><spage>143</spage><epage>151</epage><pages>143-151</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>Galactomannan (GM) is a polysaccharide present in the cell wall of
Aspergillus
spp. that is released during growth of the organism. It has been successfully used to aide in the diagnosis of invasive aspergillosis allowing for earlier recognition of disease compared to conventional methods. Since its implementation in the clinic as a diagnostic tool, GM has been used in experimental models to measure therapeutic response. Several clinical studies describe the prognostic value of GM. Herein, we review the evidence supporting the utilization of GM antigen as a biomarker to measure response to systemic antifungal therapy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28181136</pmid><doi>10.1007/s10928-017-9509-1</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4493-4652</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-567X |
| ispartof | Journal of pharmacokinetics and pharmacodynamics, 2017-04, Vol.44 (2), p.143-151 |
| issn | 1567-567X 1573-8744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1891872194 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antifungal Agents - pharmacology Aspergillosis - drug therapy Aspergillus Aspergillus - drug effects Aspergillus - metabolism Biochemistry Biomarkers - metabolism Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Humans Mannans - metabolism Pharmacology/Toxicology Pharmacy Prognosis Review Paper Veterinary Medicine/Veterinary Science |
| title | Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A28%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20galactomannan:%20current%20evidence%20for%20monitoring%20response%20to%20antifungal%20therapy%20in%20patients%20with%20invasive%20aspergillosis&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=Kovanda,%20Laura%20L.&rft.date=2017-04-01&rft.volume=44&rft.issue=2&rft.spage=143&rft.epage=151&rft.pages=143-151&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1007/s10928-017-9509-1&rft_dat=%3Cproquest_cross%3E4321356049%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1882885427&rft_id=info:pmid/28181136&rfr_iscdi=true |